Western blot shows lysates of MDA‑MB‑231 human breast cancer cell line and human placenta tissue. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human Neuropilin‑1 Antigen Affinity-purified ...read more
Neuropilin-1 was detected in immersion fixed paraffin-embedded sections of human pancreatic cancer tissue using Sheep Anti-Human Neuropilin-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3870) at 10 µg/mL ...read more
HUVEC human umbilical vein endothelial cells were stained with Sheep Anti-Human Neuropilin‑1 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF3870, filled histogram) or control antibody (Catalog # 5-001-A, ...read more
Neuropilin‑1 was detected in immersion fixed PC-3 human prostate cancer cell line (positive staining) and HLDM-2 human Hodgkin's lymphoma cell line (negative staining) using Sheep Anti-Human Neuropilin‑1 ...read more
Mouse myeloma cell line NS0-derived recombinant human Neuropilin‑1 Phe22-Lys644 Accession # NP_001019799
Detects human Neuropilin-1 in direct ELISAs and Western blots. In direct ELISAs, less than 50% cross-reactivity with recombinant rat Neuropilin-1 and recombinant mouse Neuropilin-1 is observed, and less than 1% cross-reactivity with recombinant human Neuropilin-2 is observed.
Details of Functionality
ActivityAssaywCitation not found None None None None None
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product or the use of this product is covered by U.S. Patents owned by The Regents of the University of California. This product is for research use only and is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or drug discovery purposes is prohibited. In order to obtain a license to use this product for such purposes, contact The Regents of the University of California.
U.S. Patent # 6,054,293, 6,623,738, and other U.S. and international patents pending.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Neuropilin-1 Antibody [Unconjugated]
Neuropilin-1 (Npn-1, previously neuropilin; also CD304/BDCA4) is a 130-140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis (1-4). The full-length 923 amino acid (aa) human Npn-1 contains a 623 aa extracellular domain (ECD) that shows 92-95% aa identity with mouse, rat, bovine, and canine Npn-1 (3, 4). The ECD contains two N-terminal CUB domains (termed a1a2), two domains with homology to coagulation factors V and VIII (b1b2) and a MAM (meprin) domain (c). C-terminally divergent splice variants with 704, 644, 609, and 551 aa lack the MAM and TM domains and are demonstrated or presumed to be soluble antagonists (1, 5-7). A 906 aa form lacks a TM segment, but secretion has not been found (8). The sema domains of Class III secreted semaphorins such as Sema3A bind Npn-1 a1a2 (9). Heparin, the heparin-binding forms of VEGF (VEGF165, VEGF-B, and VEGF-E), PlGF (PlGF‑2), and the C-terminus of Sema3 bind the b1b2 region (9, 10). Npn-1 and Npn-2 share 48% aa identity within the ECD and can form homo- and hetero-oligomers via interaction of their MAM domains (1). Neuropilins show partially overlapping expression in neuronal and endothelial cells during development (1, 2). Both neuropilins act as co-receptors with plexins, mainly plexin A3 and A4, to bind class III semaphorins that mediate axon repulsion (11). However, only Npn-1 binds Sema3A, and only Npn-2 binds Sema3F (1). Both are co-receptors with VEGF R2 (also called KDR or Flk-1) for VEGF165 binding (1). Sema3A signaling can be blocked by VEGF165, which has higher affinity for Npn-1 (12). Npn-1 is preferentially expressed in arteries during development or those undergoing remodeling (1, 2). Npn-1 is also expressed on dendritic cells and mediates DC-induced T cell proliferation (13).
Bielenberg, D.R. et al. (2006) Exp. Cell Res. 312:584.
Gu, C. et al. (2003) Dev. Cell 5:45.
He, Z. and M. Tessier-Lavigne (1997) Cell 90:739.
Soker, S. et al. (1998) Cell 92:735.
Gagnon, M.L. et al. (2000) Proc. Natl. Acad. Sci. USA 97:2573.
Cackowski, F.C. et al. (2004) Genomics 84:82.
Rossignol, M. et al. (2000) Genomics 70:211.
Tao, Q. et al. (2003) Angiogenesis 6:39.
Gu, C. et al. (2002) J. Biol. Chem. 277:18069.
Mamluk, R. et al. (2002) J. Biol. Chem. 277:24818.
Yaron, A. et al. (2005) Neuron 45:513.
Narazaki, M. and G. Tosato (2006) Blood 107:3892.
Tordjman, R. et al. (2002) Nat. Immunol. 3477.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Neuropilin-1 Antibody [Unconjugated] and receive a gift card or discount.